Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment;… Read more
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Asset Resilience Ratio
Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) has an Asset Resilience Ratio of 16.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sunshine Guojian Pharmaceutical Shanghai Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.48 Billion | 16.77% |
| Total Liquid Assets | CN¥1.48 Billion | 16.77% |
Asset Resilience Insights
- Good Liquidity Position: Sunshine Guojian Pharmaceutical Shanghai Co Ltd maintains a healthy 16.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sunshine Guojian Pharmaceutical Shanghai Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sunshine Guojian Pharmaceutical Shanghai Co Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Sunshine Guojian Pharmaceutical Shanghai Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.26% | CN¥910.54 Million | CN¥5.97 Billion | -2.61pp |
| 2023-12-31 | 17.87% | CN¥948.06 Million | CN¥5.31 Billion | -11.28pp |
| 2022-12-31 | 29.15% | CN¥1.49 Billion | CN¥5.10 Billion | +13.77pp |
| 2021-12-31 | 15.38% | CN¥752.05 Million | CN¥4.89 Billion | -3.44pp |
| 2020-12-31 | 18.83% | CN¥932.63 Million | CN¥4.95 Billion | +11.29pp |
| 2019-12-31 | 7.54% | CN¥250.35 Million | CN¥3.32 Billion | +6.91pp |
| 2017-12-31 | 0.63% | CN¥21.01 Million | CN¥3.34 Billion | -6.76pp |
| 2016-12-31 | 7.38% | CN¥213.36 Million | CN¥2.89 Billion | +4.71pp |
| 2015-12-31 | 2.67% | CN¥68.73 Million | CN¥2.57 Billion | +1.80pp |
| 2014-12-31 | 0.87% | CN¥20.00 Million | CN¥2.29 Billion | -0.45pp |
| 2013-12-31 | 1.32% | CN¥30.00 Million | CN¥2.28 Billion | -2.55pp |
| 2006-12-31 | 3.87% | CN¥20.00 Million | CN¥516.86 Million | -- |